ACE-031 Peptide Research – Complete Guide

Table of Contents

• Quick Facts
• What is ACE-031?
• Molecular Structure and Core Properties
• Mechanisms of Action Being Investigated
• Major Areas of Research
• Pharmacokinetics and Biological Distribution
• Research Limitations and Evidence Gaps
• Regulatory and Research Status
• Key Research Findings
• Frequently Asked Questions
• References

Quick Facts

• Primary Research Areas: Skeletal muscle hypertrophy, neuromuscular disease (DMD, ALS), sarcopenia, cancer cachexia, bone mineral density, metabolic regulation
• First Developed: Acceleron Pharma, early 2000s; Phase 1 human trial initiated 2009
• Molecular Weight: ~57,320 g/mol
• Research Status: Clinical development discontinued (2011-2013); available for laboratory research only
• Key Mechanisms: Soluble decoy receptor sequestering myostatin (GDF-8), activin A, GDF-11, BMP-2, BMP-7, and related TGF-beta superfamily ligands
• Published Studies: Phase 1 (healthy postmenopausal women, 2013); Phase 2 DMD trial (2017, terminated); multiple preclinical publications in murine and marmoset models
• Clinical Trial Status: All human trials discontinued; no active trials; Phase 2 DMD study terminated due to vascular adverse events
• Regulatory Classification: Not FDA-approved; research use only; WADA prohibited (Section S4.3)
• Half-Life: 10-15 days confirmed in human pharmacokinetic studies
• Also Known As: ActRIIB-IgG1, Soluble Activin Receptor Type IIB

What is ACE-031?

ACE-031 is a recombinant fusion protein developed by Acceleron Pharma to inhibit myostatin and multiple related growth-limiting proteins simultaneously. Unlike conventional short-chain peptides, ACE-031 is a large biological construct combining two distinct functional regions: the extracellular ligand-binding domain of human activin receptor type IIB (ActRIIB) and the constant Fc region of human immunoglobulin G1 (IgG1). While categorized as a peptide for research library purposes consistent with this site’s convention, ACE-031 is technically a recombinant fusion protein with a molecular weight of approximately 57 kDa. The core research rationale behind ACE-031 stems from the biology of myostatin, a protein the body uses to suppress excessive muscle growth. Myostatin acts as a biological brake on skeletal muscle, and animals or humans who lack functional myostatin develop dramatically larger muscles. Researchers identified myostatin inhibition as a potential therapeutic strategy for muscle-wasting diseases in the 1990s, and ACE-031 emerged as one of the most potent approaches to block this pathway [7]. What distinguishes ACE-031 from earlier myostatin inhibitors is its broad-spectrum activity. Rather than targeting myostatin alone, ACE-031 intercepts myostatin plus several structurally related proteins (activin A, GDF-11, BMP-2, BMP-7) that share the same receptor system and collectively suppress muscle growth. This multi-ligand blockade produced stronger anabolic effects in preclinical models than any myostatin-specific antibody [5], but it also introduced complexity: some of the proteins ACE-031 captures serve important roles in vascular biology, and their inhibition generated unwanted blood vessel side effects in human trials. ACE-031 peptide research advanced through Phase 1 human studies in 2009, with FDA Orphan Drug and Fast Track designations for Duchenne muscular dystrophy (DMD) obtained in 2010 based on preclinical evidence supporting the compound’s potential in this population [7]. A Phase 2 trial in DMD patients followed. Development was halted in 2011 after vascular adverse events emerged in the second dosing cohort. Acceleron and Shire PLC formally terminated their collaboration in 2013, and no pharmaceutical sponsor has resumed clinical development since. ACE-031 now serves as a scientifically important research tool. Its clinical trial data, combined with extensive preclinical work, provides researchers with detailed quantitative insights into how the TGF-beta superfamily regulates muscle mass, bone density, fat metabolism, and vascular function simultaneously. The compound is classified for laboratory research use only and is prohibited in competitive sport by WADA.

Molecular Structure and Core Properties

Chemical Structure and Specifications

Property	Specification
Molecular Formula	C3418H5188N928O1062S38
Molecular Weight	~57,320 g/mol
CAS Number	1621169-52-5
Protein Classification	Recombinant fusion protein (decoy receptor)
Component 1	Extracellular domain of human ActRIIB (activin receptor type IIB)
Component 2	Fc region of human immunoglobulin G1 (IgG1)
Half-Life	10-15 days (confirmed in human Phase 1 studies)
Solubility	Water soluble; administered subcutaneously in clinical studies
Stability	Stable under standard biopharmaceutical storage conditions

Key Structural Features

ACE-031’s large molecular weight (~57 kDa) reflects its status as a fusion protein rather than a conventional short peptide. The ActRIIB extracellular domain provides the functional core: a precisely folded binding pocket that captures TGF-beta superfamily ligands with high affinity before they can reach cell-surface receptors on muscle and other tissues. This region determines which ligands ACE-031 can sequester, including myostatin, activin A, GDF-11, BMP-2, and BMP-7 among the primary targets [11]. The IgG1-Fc region serves a pharmacokinetic purpose rather than a binding function. Fusing the Fc domain to the receptor fragment dramatically extends the compound’s circulation time by exploiting the neonatal Fc receptor (FcRn) recycling pathway, which normally prolongs antibody half-lives. This engineering choice extends ACE-031’s half-life to 10-15 days, far longer than most peptide therapeutics, enabling dosing intervals measured in weeks rather than hours [1]. The same broad binding affinity that makes ACE-031 more potent than selective myostatin inhibitors also creates its selectivity challenge. BMP-9 and BMP-10, which are critical for endothelial cell stability and vascular integrity, share structural similarities with the intended targets. ACE-031 captures these vascular BMPs as well, disrupting endothelial signaling and producing the telangiectasias and epistaxis observed in human trials [2].

Mechanisms of Action Being Investigated

ACE-031 operates through a fundamentally different strategy than receptor-blocking antibodies or small molecule inhibitors. Rather than occupying cell-surface receptors, it functions as a circulating molecular trap that removes inhibitory ligands from the bloodstream before they can engage muscle cells.

Decoy Receptor Sequestration of Myostatin (GDF-8)

Myostatin is the primary research target. Under normal physiological conditions, myostatin binds ActRIIB receptors on skeletal muscle fibers, recruiting co-receptors ALK4 or ALK5, which phosphorylate intracellular SMAD2 and SMAD3 proteins. Phosphorylated SMAD2/3 form a complex with SMAD4 and translocate to the cell nucleus, where they suppress the expression of myogenic genes responsible for muscle growth and protein synthesis [13]. ACE-031 intercepts myostatin extracellularly, preventing this entire signaling cascade. Without SMAD2/3 activation, the transcriptional repression of muscle-building genes is removed. Satellite cells (muscle stem cells) activate more readily, myoblasts differentiate into mature muscle fibers without inhibition, and protein synthesis proceeds at elevated rates. This mechanism produces what researchers describe as disinhibition of muscle growth rather than active stimulation of a separate anabolic pathway [1].

Multi-Ligand Blockade: Activin A, GDF-11, BMP-2, and BMP-7

Activin A shares the ActRIIB receptor with myostatin and similarly restricts muscle growth through SMAD2/3 signaling. ACE-031’s capture of activin A contributes meaningfully to its superior anabolic potency compared to myostatin-selective antibodies [10]. A pharmacodynamic consequence of activin A inhibition observed in clinical trials was a 43% reduction in follicle-stimulating hormone (FSH), because activin A normally promotes FSH release from the pituitary gland [2]. GDF-11 is structurally similar to myostatin and serves as an additional negative regulator of muscle mass. BMP-2 and BMP-7, while better known for bone morphogenetic roles, also engage ActRIIB and contribute to constraints on muscle protein synthesis. Simultaneous neutralization of these four ligands alongside myostatin explains why ACE-031 produces stronger muscle mass effects than any single-target approach studied to date [3].

Vascular Off-Target Inhibition: BMP-9 and BMP-10

ACE-031’s binding affinity extends to BMP-9 and BMP-10, which are not intended targets but share enough structural similarity with the primary ligands that ACE-031 captures them as well. BMP-9 and BMP-10 are essential for endothelial cell stability, arteriovenous differentiation, and maintenance of vessel wall integrity through the ALK1 receptor pathway. Their sequestration disrupts endothelial signaling, producing the telangiectasias (abnormal small vessel dilations), epistaxis (nosebleeds), and gum bleeding observed in Phase 2 trial participants [2]. This off-target mechanism is the fundamental selectivity problem that ended ACE-031’s clinical development.

SMAD Pathway Disruption and Anabolic Signaling

By removing the extracellular ligands that drive SMAD2/3 activation, ACE-031 de-represses the anabolic gene programs that myostatin normally suppresses. Research in animal models indicates this disinhibition enhances IGF-1 receptor signaling, activates mTOR pathways supporting protein synthesis, reduces proteolytic enzyme activity that breaks down muscle proteins, and increases overall muscle protein balance [3].

ERK1/2 Pathway and Muscle Preservation

Preclinical research suggests ACE-031 prevents muscle fiber loss by blocking ERK1/2-mediated apoptotic signaling in muscle cells [3]. This anti-atrophic effect appears to operate independently of the hypertrophic mechanism, meaning ACE-031 may both promote growth and prevent breakdown simultaneously, contributing to the substantial lean mass gains documented in animal studies.

Bone Mechanism

ACE-031’s effects on bone tissue appear largely independent of its muscle effects. Phase 1 human data showed a 3.4% increase in lumbar spine bone mineral density in treated groups compared to a 1.5% decrease in placebo controls. Bone formation markers (osteocalcin, P1NP) increased while bone resorption markers (CTX, NTX) decreased, indicating ACE-031 shifts bone metabolism toward net formation by suppressing osteoclast activity. TGF-beta superfamily ligands including activin A and myostatin promote osteoclast function, so their sequestration removes a pro-resorption signal from bone tissue. Koncarevic et al. (2012) demonstrated this bone-protective effect specifically for soluble ActRIIB in the context of androgen deprivation, confirming that ActRIIB pathway inhibition prevents both muscle and bone loss [1,11].

Adipose Tissue and Metabolic Mechanisms

TGF-beta superfamily signaling promotes adipogenesis (fat cell formation) and favors energy-storing white adipose tissue. ACE-031 inhibition of these pathways shifts adipose metabolism, reducing new fat cell formation and potentially promoting conversion from white to thermogenic brown adipose characteristics in preclinical models. Elevated basal oxygen consumption measured by phosphorus-31 magnetic resonance spectroscopy in treated animals supports a metabolic shift toward increased energy expenditure [3].

Major Areas of Research

ACE-031 has been studied across neuromuscular disease, cancer-related muscle wasting, bone biology, metabolic research, and muscle physiology. The following sections summarize each area at a primer level; each represents a candidate for deeper standalone analysis.

Duchenne Muscular Dystrophy Research

DMD represents ACE-031’s most extensively studied human application. DMD is an X-linked genetic disorder causing progressive muscle fiber destruction due to absent dystrophin protein. Affected boys typically lose ambulation in their early teens, and respiratory or cardiac muscle failure follows in young adulthood. ACE-031 reached a Phase 2 randomized, placebo-controlled trial (NCT01099761) in ambulatory boys with DMD administered subcutaneously every 2-4 weeks. Interim results showed trends for maintenance of 6-minute walk test performance compared to functional decline in placebo-treated controls, alongside increased lean body mass and thigh muscle volume by MRI [2]. The trial was terminated after the second dosing cohort when vascular adverse events became apparent. No peer-reviewed publication documents completed efficacy outcomes for DMD, meaning ACE-031’s therapeutic potential in this population remains formally unproven. Preclinical work in mdx mice (the established DMD animal model) provided the scientific foundation for the human trial. Studies in mdx mice using 10 mg/kg doses showed substantial increases in muscle mass, fiber cross-sectional area, and force generation, providing proof-of-concept that myostatin pathway inhibition could counteract dystrophic muscle loss [3]. Key Research Highlights:

• Phase 2 interim data showed functional maintenance trends vs. placebo decline [2]
• Vascular adverse event profile in the clinical trial ended development before efficacy was formally established
• mdx mouse studies showed up to 50% improvements in maximum force generation [3]
• Amthor and Hoogaars (2012) outlined the scientific rationale for ActRIIB interference as a therapeutic strategy in DMD [7]

ALS and Neuromuscular Wasting Models

Amyotrophic lateral sclerosis (ALS) is a progressive motor neuron disease causing muscle denervation and wasting. ACE-031 has been tested in preclinical ALS models, where administration of a soluble activin type IIB receptor demonstrated prevention of muscle wasting and improvement in motor function endpoints, as documented by Cadena et al. (2010) across multiple atrophy model conditions [3]. The rationale is preserving functional muscle mass during motor neuron degeneration, potentially extending the period of mobility and respiratory function. Research in these models showed ACE-031 maintained muscle architecture and contractile function even as motor neuron degeneration progressed. Whether these preclinical effects would translate to humans remains unknown, as no clinical trials in ALS have been conducted. Key Research Highlights:

• Prevention of muscle wasting documented in preclinical neuromuscular atrophy models [3]
• Improved motor function endpoints in preclinical studies [3]
• No human ALS trial data available

Sarcopenia and Age-Related Muscle Loss

Sarcopenia, the progressive loss of skeletal muscle mass and function with aging, represents a major research application for myostatin pathway inhibitors [15]. Myostatin expression increases with age, and the associated SMAD2/3 signaling contributes to impaired satellite cell function and reduced muscle regenerative capacity in older individuals. ACE-031’s Phase 1 study enrolled healthy postmenopausal women, a population with established muscle loss, and documented significant lean mass gains and muscle volume increases from a single dose. The compound’s ability to restore muscle mass in this demographic supports the hypothesis that myostatin pathway inhibition could counteract sarcopenia, though no dedicated sarcopenia trial was conducted before development ceased [1]. Key Research Highlights:

• Phase 1 data in postmenopausal women showed 3.3% lean mass increase and 5.1% thigh volume increase from a single dose [1]
• Multi-week pharmacodynamic effects suggest potential for infrequent dosing in aging populations
• No dedicated sarcopenia clinical trial completed

Cancer Cachexia Research

Cancer cachexia, the muscle and fat wasting syndrome affecting up to 80% of advanced cancer patients, significantly reduces treatment tolerance and survival [16]. Myostatin and activin A levels increase in tumor-bearing states, and their combined elevation accelerates muscle catabolism. ACE-031 neutralizes both myostatin and activin A simultaneously, making it theoretically suited to address multiple drivers of cachexia-associated muscle loss. Zhou et al. (2010) demonstrated in tumor-bearing animal models that ActRIIB antagonism reversed cancer cachexia, preserved muscle mass during tumor progression, and prolonged survival, providing preclinical support for this research direction [8]. Studies also showed ACE-031 offset dexamethasone-induced muscle loss, producing an 11% increase in lean mass even during concurrent corticosteroid treatment, which is directly relevant to cancer supportive care contexts [3]. Key Research Highlights:

• Reversal of cancer cachexia and preserved muscle mass in tumor-bearing animal models [8]
• 11% lean mass increase during concurrent glucocorticoid treatment in animal studies [3]
• Dual inhibition of myostatin and activin A addresses multiple cachexia mechanisms
• No human cancer cachexia trial data available

Bone Mineral Density and Osteoporosis Research

ACE-031 produced unexpected bone density improvements in Phase 1 human studies, establishing bone biology as a secondary but scientifically significant research area. The 3.4% increase in lumbar spine bone mineral density after a single dose, compared to a 1.5% decrease in placebo controls, represents a clinically meaningful magnitude of effect [1]. The bone mechanism is mediated through activin A and myostatin inhibition, both of which promote osteoclast activity under normal conditions. Koncarevic et al. (2012) demonstrated specifically that soluble ActRIIB prevents the effects of androgen deprivation on body composition and bone health, showing that ActRIIB pathway inhibition shifts bone metabolism toward net formation by removing pro-resorption signals [11]. Bone formation markers (osteocalcin, P1NP) increased within weeks of dosing, while resorption markers (CTX, NTX) decreased. Researchers study this finding in the context of conditions where muscle loss and bone loss co-occur, including aging, immobilization, glucocorticoid use, and cancer treatment. ACE-031’s simultaneous effects on both muscle and bone make it a useful tool for studying the mechanistic links between these two tissue systems. Key Research Highlights:

• 3.4% lumbar spine bone mineral density increase after a single human dose [1]
• Simultaneous increase in bone formation markers and decrease in bone resorption markers
• Koncarevic et al. confirmed soluble ActRIIB prevents bone loss under androgen deprivation conditions [11]

Metabolic Research: Adipose Tissue and Insulin Sensitivity

ACE-031 alters fat metabolism through TGF-beta pathway inhibition in adipose tissue. Preclinical studies documented reduced adipogenesis, altered lipid metabolism biomarkers, and evidence of enhanced thermogenic capacity [3]. The proposed mechanism involves white-to-brown adipose conversion, where energy-storing white fat cells acquire characteristics of thermogenic brown fat cells, increasing basal energy expenditure. Potential improvements in insulin sensitivity have been observed in preclinical metabolic models, likely secondary to improved body composition (increased muscle mass, reduced fat mass) and the direct effects of reduced TGF-beta signaling on insulin receptor substrate pathways. These metabolic findings have not been formally investigated in human metabolic disease populations. Key Research Highlights:

• Reduced adipogenesis and altered lipid metabolism biomarkers in preclinical studies [3]
• Potential white-to-brown adipose conversion increasing thermogenic activity
• Elevated basal oxygen consumption measured by phosphorus-31 magnetic resonance spectroscopy in animal studies, as reported by Cadena et al. (2010) [3]

Muscle Physiology: Force Generation and Fiber Architecture

A critical distinction in ACE-031 research is its effect on contractile force relative to muscle mass. Myostatin-knockout mice develop substantially larger muscles, but the specific force (force per unit muscle cross-sectional area) is often reduced or unchanged, suggesting the additional muscle mass is not fully functional [5]. ACE-031-treated common marmosets showed both fiber hypertrophy and proportional improvements in contractile force. Type II muscle fiber cross-sectional area increased by 20% and type I fibers increased by 34%, while both absolute and specific twitch and tetanic forces improved in treated animals compared to controls [3]. This suggests multi-ligand TGF-beta inhibition produces functionally superior muscle rather than simply larger muscle, a distinction with important implications for neuromuscular disease research where functional preservation matters as much as mass. Myosin heavy chain profiles and fiber type distribution were not significantly altered by ACE-031 treatment in these studies, distinguishing its mechanism from anabolic agents that shift fiber type composition [3]. Key Research Highlights:

• 20% increase in type II and 34% increase in type I muscle fiber cross-sectional area in marmoset studies [3]
• Proportional improvements in both muscle mass and contractile force (unlike myostatin-knockout models) [5]
• No significant fiber type distribution changes [3]

Pharmacokinetics and Biological Distribution

Absorption and Bioavailability

ACE-031 was administered subcutaneously in all human clinical studies. Subcutaneous absorption of large fusion proteins typically occurs through lymphatic uptake before entering systemic circulation, producing a gradual rise to peak plasma concentrations over 24-72 hours. Pharmacokinetics were linear across the full dose range tested in Phase 1 (0.02-3 mg/kg), with area under the curve (AUC) and maximum plasma concentration (Cmax) increasing proportionally with dose [1]. This linearity indicates predictable plasma exposure across the studied dose range, a pharmacokinetically favorable characteristic for research applications requiring reproducible systemic concentrations.

Distribution and Metabolism

ACE-031’s IgG1-Fc component exploits the neonatal Fc receptor (FcRn) recycling pathway, which returns antibodies and Fc-fusion proteins from endosomes back into circulation rather than allowing lysosomal degradation. This mechanism is the primary reason for the 10-15 day half-life confirmed in Phase 1 human studies [1]. At ~57,320 g/mol, ACE-031 is too large for glomerular filtration and urinary excretion of intact protein. Anti-doping detection research confirmed that no intact ACE-031 protein is recoverable from urine at any timepoint, consistent with this molecular size constraint [6]. The compound distributes primarily in the vascular compartment and extracellular fluid, with ligand sequestration occurring in circulation rather than inside cells.

Delivery Methods Under Investigation

• Subcutaneous injection: The route used in all human clinical studies; produces gradual systemic absorption with sustained plasma levels consistent with the long half-life
• Intraperitoneal injection: Used in rodent research models; produces rapid systemic distribution
• Intravenous administration: Used in some preclinical studies; bypasses absorption phase

No oral bioavailability has been demonstrated for ACE-031; proteins of this size are degraded in the gastrointestinal tract before absorption.

Excretion and Clearance

ACE-031 undergoes proteolytic degradation through standard protein catabolism pathways rather than renal or hepatic elimination of intact compound. The IgG1-Fc region provides protection from this degradation through FcRn recycling, but the compound is eventually cleared as the Fc-recycling capacity is saturated over weeks. Anti-doping research in rodent models detected ACE-031 in serum for at least 48 hours after single-dose administration, with undetectable levels by 7 days (168 hours) in that species [6]. Human clearance is considerably slower given the 10-15 day half-life. Pharmacodynamic effects (muscle volume, bone biomarker changes) persist for substantially longer than detectable plasma concentrations, suggesting sustained downstream signaling effects after the compound itself has cleared.

Research Limitations and Evidence Gaps

Current Research Gaps

Human Clinical Data ACE-031 peptide research in humans halted at Phase 2, leaving fundamental questions unanswered for every intended application. The DMD Phase 2 trial was terminated before efficacy endpoints were reached, meaning therapeutic benefit in that population is formally unproven. No Phase 2 or Phase 3 data exist for sarcopenia, ALS, cancer cachexia, or any other indication. The Phase 1 dataset comes from healthy postmenopausal women, a population not representative of the disease states ACE-031 was designed to treat. The vascular adverse event profile (telangiectasias, epistaxis, gum bleeding) observed after repeated dosing has not been fully characterized. The dose-response relationship for vascular toxicity, the duration of vascular effects after discontinuation, and individual risk factors for susceptibility are unknown [2]. Mechanistic Understanding The contribution of each individual ligand (myostatin, activin A, GDF-11, BMP-2, BMP-7) to total muscle mass effects has not been cleanly dissected in humans [10]. The relative contributions of BMP-9 and BMP-10 inhibition to vascular toxicity versus potential therapeutic benefit remain incompletely understood. Whether vascular adverse events could be mitigated by dose reduction, modified dosing schedules, or engineered selectivity improvements is untested [14]. The 43% FSH reduction observed in clinical studies has not been studied for long-term endocrine consequences. Effects on reproductive hormones in premenopausal populations, male subjects, or pediatric patients remain unstudied [2]. Methodological Considerations Most preclinical data comes from rodent models that differ substantially from human muscle physiology, particularly in fiber type distribution and regenerative capacity. The marmoset study, while more translationally relevant than rodent data, represents a single study in a small primate species. Species-specific differences in TGF-beta pathway regulation limit extrapolation from animal data to human outcomes [15]. All clinical data derives from a single company’s development program, with no independent replication in human subjects. Long-term effects beyond the 29-day primary endpoint of Phase 1 studies are unknown in humans.

Areas Needing Further Investigation

• Human safety characterization at doses below those triggering vascular events: the therapeutic window between efficacy and vascular toxicity has not been defined
• Vascular toxicity mechanism clarification: whether BMP-9/10 inhibition is solely responsible or whether additional mechanisms contribute
• Effects in male subjects and premenopausal populations: all human data comes from postmenopausal women and a small cohort of boys (DMD trial, terminated early)
• Long-term bone and muscle effects beyond 30 days in humans: single-dose data cannot support conclusions about sustained treatment [15]
• Pediatric pharmacokinetics and safety: the DMD trial was terminated before adequate pediatric safety data was collected
• Whether engineered variants with improved selectivity (sparing BMP-9/BMP-10) could preserve the anabolic effects without vascular consequences [14]

Regulatory and Research Status

Current Classification

FDA Status ACE-031 holds historical FDA Orphan Drug Designation and Fast Track designation for DMD, both obtained in 2010. These designations have no current practical significance because clinical development has been permanently discontinued. ACE-031 is an unapproved investigational new drug with no active IND. It is not approved for any human therapeutic use, not available through any licensed pharmacy or compounding facility, and not authorized for veterinary use. The compound is classified for legitimate laboratory research use only. WADA Status WADA explicitly prohibits ACE-031 in competitive athletics under Section S4.3 of the Prohibited List: “Agents Preventing Activin Receptor IIB Activation.” ACE-031 is specifically named as a prohibited decoy activin receptor and is banned at all times, both in-competition and out-of-competition, with no Therapeutic Use Exemptions available [17]. Validated detection methods using gel electrophoresis have been published and are available to anti-doping laboratories [6]. International Perspective The European Medicines Agency (EMA) never received an active marketing authorization application for ACE-031. Most major regulatory jurisdictions classify it as an unapproved biological therapeutic, restricting its use to research contexts. Regulatory frameworks for large biological fusion proteins in research settings are generally more complex than for conventional peptides, requiring institutional biosafety review and appropriate handling protocols.

Research Community Approach

Academic research using ACE-031 as a laboratory tool continues at research institutions investigating TGF-beta superfamily biology, neuromuscular disease pathophysiology, and muscle-bone regulatory networks. This research uses ACE-031 as a pharmacological probe to dissect biological pathways rather than as a therapeutic candidate. Institutional biosafety committees and ethical oversight boards govern legitimate research use. The compound’s defined pharmacological profile, established clinical-grade pharmacokinetic data, and extensive preclinical dataset make it a scientifically valuable tool despite its terminated clinical trajectory.

Future Research Directions

The principal scientific lesson from ACE-031’s development is that broad ActRIIB ligand inhibition achieves superior anabolic potency but at the cost of vascular safety. Acceleron Pharma and other developers subsequently pursued engineered variants with improved selectivity profiles aimed at retaining anabolic effects while sparing BMP-9 and BMP-10 [14]. These next-generation approaches represent the active frontier of ActRIIB-pathway drug development. ACE-031 itself serves research as a well-characterized reference compound defining the upper bound of multi-ligand TGF-beta inhibition and its associated pharmacological consequences.

Key Research Findings

Phase 1 Single-Dose Human Study: Lean Mass and Bone Density

Research Focus: Safety, pharmacokinetics, and pharmacodynamic effects of single subcutaneous doses in healthy postmenopausal women (0.02-3 mg/kg) Key Results: At 3 mg/kg, 3.3% increase in total lean body mass by DXA (P = 0.03) and 5.1% increase in thigh muscle volume by MRI (P = 0.03) at 29 days after a single dose; 3.4% lumbar spine bone mineral density increase versus 1.5% decrease in placebo; linear pharmacokinetics across all doses; 10-15 day half-life confirmed. Significance: Established ACE-031 peptide research as producing measurable, statistically significant changes in human muscle mass and bone density from a single administration, demonstrating potent pharmacodynamic activity in humans. Limitations: Healthy postmenopausal women only; 29-day follow-up; no long-term safety data; single-dose study cannot address repeated-dosing effects [1].

Phase 2 DMD Trial: Efficacy Trends and Vascular Events

Research Focus: Safety and preliminary efficacy in ambulatory boys with Duchenne muscular dystrophy, dosing every 2-4 weeks Key Results: Trends toward maintained 6-minute walk test performance versus placebo decline; increased lean mass and thigh muscle volume; 43% reduction in FSH from activin A inhibition; vascular adverse events (epistaxis, telangiectasias, gum bleeding, skin erythema) in second dosing cohort leading to trial termination; all vascular events resolved on discontinuation. Significance: First repeated-dosing human data; identified the vascular safety signal that ended clinical development; established FSH suppression as a pharmacodynamic consequence of activin A inhibition. Limitations: Trial terminated before efficacy endpoints reached; efficacy in DMD formally unproven; no completed peer-reviewed efficacy publication [2].

Common Marmoset Preclinical Study: Functional Muscle Quality

Research Focus: 14-week ACE-031 treatment effects on muscle mass, fiber morphology, and contractile function in common marmosets Key Results: Type II muscle fiber cross-sectional area increased 20%; type I fiber cross-sectional area increased 34%; significant improvements in both absolute and specific twitch and tetanic isometric forces in extensor digitorum longus muscles; no major adverse changes in blood chemistries. Significance: Demonstrated that multi-ligand TGF-beta inhibition produces proportional improvements in both muscle mass and contractile force, distinguishing ACE-031’s functional profile from myostatin-knockout models where specific force is not proportionally improved. Limitations: Single species; small primate model; no direct comparison arm with selective myostatin inhibitor in the same study [3].

Murine Preclinical Studies: Force Generation and Atrophy Prevention

Research Focus: ACE-031 at 10 mg/kg in mdx mice and other murine strains; atrophy models including glucocorticoid treatment and ALS model conditions Key Results: Up to 50% increases in maximum force generation; 25% increases in total contractile force; 11% lean mass increase during concurrent dexamethasone treatment; prevention of muscle wasting and improved motor function in neuromuscular atrophy models; no changes in myosin heavy chain profiles or fiber type distribution. Phosphorus-31 magnetic resonance spectroscopy documented elevated basal oxygen consumption in treated animals [3]. Significance: Established dose-dependent muscle mass and strength effects across multiple atrophy models; demonstrated preservation of muscle architecture and function; showed ACE-031 can offset glucocorticoid-induced muscle catabolism. Limitations: Rodent models differ substantially from human muscle physiology; 10 mg/kg doses significantly exceed those used in human studies [3].

Anti-Doping Detection Study: WADA Compliance

Research Focus: Development and validation of detection methods for ACE-031 in biological samples relevant to sports drug testing Key Results: Gel electrophoretic methods validated for ACE-031 detection in serum; detectable for at least 48 hours after single-dose administration in rats; undetectable by 7 days in rodent models; no intact protein detectable in urine at any timepoint due to molecular size exceeding glomerular filtration threshold. Significance: Confirms WADA’s ability to enforce its prohibition of ACE-031 in competitive sport; establishes detection window parameters relevant to anti-doping testing programs. Limitations: Rodent detection windows; human detection windows may differ substantially given the 10-15 day half-life [6].

Comparative Mechanism: Multi-Ligand vs. Selective Myostatin Inhibition

Research Focus: Mechanistic comparison of broad ActRIIB inhibition versus selective myostatin blockade Key Results: Myostatin-deficient mice show limited improvement in specific force (force per unit muscle cross-sectional area) despite large mass gains [5]; ACE-031-treated animals show proportional improvement in both mass and functional force; additional ligand inhibition (activin A, GDF-11, BMP-2, BMP-7) appears necessary for full anabolic effect and functional muscle quality [10]. Significance: Explains why ACE-031 produces superior functional outcomes compared to myostatin-selective antibodies, and why multi-ligand approaches warrant continued investigation despite ACE-031’s specific development failure. Limitations: Cross-study comparison; species differences between knockout mouse and ACE-031-treated marmoset models complicate direct interpretation [3].

Frequently Asked Questions

What is ACE-031 and what was it originally developed for?

ACE-031 is a laboratory-engineered fusion protein designed to block myostatin, a natural protein that limits skeletal muscle growth. It was originally developed by Acceleron Pharma as a potential treatment for Duchenne muscular dystrophy, a progressive muscle-wasting disease in boys. The compound received FDA Orphan Drug and Fast Track designations before its clinical development was discontinued in 2011-2013 following safety concerns in human trials.

Why did ACE-031 clinical trials stop?

Human trials were halted after participants in the Phase 2 DMD study experienced vascular side effects including nosebleeds, telangiectasias (small dilated blood vessels visible under the skin), and gum bleeding after repeated dosing. These effects occurred because ACE-031 is a broad-spectrum inhibitor that captures not only myostatin but also proteins essential for maintaining blood vessel wall integrity. Although the adverse events resolved when dosing stopped, Acceleron Pharma and its partner Shire PLC determined the risk profile was not acceptable for continued development, and formally ended the program in 2013.

Is ACE-031 available for human use today?

No. ACE-031 is not approved by any regulatory agency for human therapeutic use and is not available through any licensed pharmacy, compounding facility, or medical provider. It is classified for laboratory research use only. Any product sold as ACE-031 for human use outside of a formal, ethics-approved research protocol operates outside established regulatory frameworks. WADA also explicitly prohibits ACE-031 in competitive athletics with no Therapeutic Use Exemptions available.

How does ACE-031 differ from other myostatin inhibitors?

Most myostatin inhibitors are antibodies or propeptide fragments designed to target myostatin specifically. ACE-031 takes a different approach, using a decoy receptor that captures myostatin plus several related proteins simultaneously (activin A, GDF-11, BMP-2, BMP-7). This multi-target approach produced stronger muscle growth effects in preclinical studies than any single-target myostatin inhibitor, but also captured proteins important for vascular function, which caused the blood vessel side effects that ended human testing. Next-generation compounds in this research area are attempting to retain the anabolic potency while improving selectivity.

What does current research show about ACE-031’s effects on bone?

An unexpected finding from the Phase 1 human study was that a single dose of ACE-031 produced a 3.4% increase in lumbar spine bone mineral density over 29 days, while placebo-treated participants showed a 1.5% decrease. Bone formation markers increased and bone resorption markers decreased, indicating a shift toward net bone building. This effect occurs because several of the proteins ACE-031 blocks also promote bone resorption under normal conditions. Researchers studying the connections between muscle and bone regulatory biology use this finding to investigate how TGF-beta superfamily signals coordinate both tissue systems simultaneously.

References

1. Attie, K.M., Borgstein, N.G., Yang, Y., Condon, C.H., Wilson, D.M., Pearsall, A.E., Kumar, R., Willins, D.A., Seehra, J.S., & Sherman, M.L. (2013). A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle & Nerve, 47(3), 416-423. PubMed
2. Campbell, C., McMillan, H.J., Mah, J.K., Tarnopolsky, M., Selby, K., McClure, T., Wilson, D.M., Sherman, M.L., Escolar, D., & Attie, K.M. (2017). Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial. Muscle & Nerve, 55(4), 458-464. PubMed
3. Cadena, S.M., Tomkinson, K.N., Monnell, T.E., Spaits, M.S., Kumar, R., Underwood, K.W., Pearsall, R.S., & Lachey, J.L. (2010). Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type. Journal of Applied Physiology, 109(3), 635-642. PubMed
4. Lee, S.J., & McPherron, A.C. (2001). Regulation of myostatin activity and muscle growth. Proceedings of the National Academy of Sciences, 98(16), 9306-9311. PubMed
5. McPherron, A.C., Lawler, A.M., & Lee, S.J. (1997). Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature, 387(6628), 83-90. PubMed
6. Reichel, C., Abzieher, F., & Geyer, H. (2025). Gel electrophoretic detection of the doping substance ACE-031 (ActRIIB-IgG1) in serum samples. Drug Testing and Analysis, 17(5), 456-465. PubMed
7. Amthor, H., & Hoogaars, W.M. (2012). Interference with myostatin/ActRIIB signaling as a therapeutic strategy for Duchenne muscular dystrophy. Current Gene Therapy, 12(3), 245-259. PubMed
8. Zhou, X., Wang, J.L., Lu, J., Song, Y., Kwak, K.S., Jiao, Q., Rosenfeld, R., Chen, Q., Boone, T., Simonet, W.S., Lacey, D.L., Goldberg, A.L., & Han, H.Q. (2010). Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell, 142(4), 531-543. PubMed
9. Latres, E., Mastaitis, J., Fury, W., Miloscio, L., Trejos, J., Pangilinan, J., Okamoto, H., Cavino, K., Na, E., Papatheodorou, A., Willer, T., Bhatt, K., Huang, H., Haber, L., Zhang, Y., Murphy, A.J., Economides, A.N., & Gromada, J. (2017). Activin A more prominently regulates muscle mass in primates than does GDF8. Nature Communications, 8, 15153. PubMed
10. Lodberg, A. (2021). Principles of the activin receptor signaling pathway and its inhibition. Cytokine & Growth Factor Reviews, 60, 1-17. PubMed
11. Koncarevic, A., Cornwall-Brady, M., Pullen, A., Davies, M., Sako, D., Liu, J., Kumar, R., Tomkinson, K., Baker, T., Umiker, B., Rovelli, G., Jasuja, R.R., Morales, C., Wipf, P., Lachey, J., & Seehra, J. (2012). A soluble activin receptor type IIb prevents the effects of androgen deprivation on body composition and bone health. Endocrinology, 153(12), 5666-5679. PubMed
12. Massague, J. (2012). TGF-beta signaling in development and disease. FEBS Letters, 586(14), 1833. PubMed
13. Lach-Trifilieff, E., Minetti, G.C., Sheppard, K., Ibebunjo, C., Feige, J.N., Hartmann, S., Brachat, S., Rivet, H., Koelbing, C., Morvan, F., Hatakeyama, S., & Glass, D.J. (2014). An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy. Molecular and Cellular Biology, 34(4), 606-618. PubMed
14. Dschietzig, T.B. (2014). Myostatin: From the secreted protein to blocking strategies and clinical applications. Current Pharmaceutical Design, 20(38), 6027-6037. PubMed
15. Visser, M., & Schaap, L.A. (2011). Consequences of sarcopenia. Clinics in Geriatric Medicine, 27(3), 387-399. PubMed
16. Waning, D.L., & Guise, T.A. (2014). Cancer-associated muscle weakness: What’s bone got to do with it? BoneKEy Reports, 3, 543. PubMed
17. World Anti-Doping Agency. (2024). Prohibited List 2024: Section S4.3 Agents Preventing Activin Receptor IIB Activation. WADA. WADA